Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Catalyst-rich 2024 with multiple clinical data readouts and updates expected for pipeline and discovery programs
Phase 2/3 Duravelo-2 registrational trial for BT8009 in metastatic urothelial cancer.
Bicycle Therapeutics plc Forecasted to Earn FY2023 Earnings of ($5 24) Per Share (NASDAQ:BCYC) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
R&D Day on December 14 to provide clinical updates for BT8009, BT5528 and BT7480, and highlight broad capabilities of novel Bicycle® technology
Alignment with FDA on expedited development and.